AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.

Carpal tunnel syndrome was linked to wild-type transthyretin amyloidosis in new research, highlighting the importance of ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

A new AI model accurately detected cardiac amyloidosis from echocardiograms with higher accuracy vs. other amyloidosis risk ...

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

In comparative analysis, EchoGo® Amyloidosis outperformed two validated clinical scoring systems, the Transthyretin Cardiac ...

The AI model effectively spotted all subtypes of amyloidosis in the dataset, with an area under the receiver-operating characteristic curve (AUROC) of 0.93, a sensitivity of 85% for identifying ...

Explore how AI transforms cardiac amyloidosis detection with remarkable accuracy—keep reading to see its clinical potential.